The effects of the NICE Technology Appraisal 121 (gliadel and temozolomide) on survival in high-grade glioma. (Q55462091)

12 July 2018

title

The effects of the NICE Technology Appraisal 121 (gliadel and temozolomide) on survival in high-grade glioma. (English)

1 reference

12 July 2018

0 references

James Geoffrey Barr

1

1 reference

12 July 2018

Paul L Grundy

series ordinal

2

1 reference

12 July 2018

publication date

21 June 2012

1 reference

12 July 2018

British Journal of Neurosurgery

published in

1 reference

12 July 2018

volume

26

1 reference

12 July 2018

issue

6

1 reference

12 July 2018

page(s)

818-822

1 reference

12 July 2018

Malignant gliomas in 2005: where to GO from here?

cites work

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.697221

Management of malignant brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.697221

Glioma invasion in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.697221

Aggressive oligodendroglioma: a chemosensitive tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.697221

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.697221

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.697221

Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.697221

Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.697221

Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.697221

Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.697221

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.697221

Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.697221

Risk factors for postcraniotomy surgical site infection after 1,3-bis (2-chloroethyl)-1-nitrosourea (Gliadel) wafer placement

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.697221

Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.697221

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.697221

10.3109/02688697.2012.697221

21 January 2018

Identifiers

DOI

1 reference

12 July 2018

1 reference

12 July 2018